Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
Cited by Finnish Environment Institute (Syke) on
At the Finnish Environment Institute (Syke), we offer strong expertise and independent information on global phenomena such as climate change, biodiversity loss, overconsumption, pollution and eutrophication.